Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing

Bone Marrow Transplantation
S GiebelF Locatelli

Abstract

We evaluated the outcome of 63 children given haematopoietic stem cell transplantation from unrelated donors (URD-HSCT) prospectively selected using DNA high-resolution typing of both HLA class I and class II loci. Thirty patient/donor pairs (48%) were fully matched. Among the others, HSCT was performed in the presence of one (n=22), two (n=9), or three (n=2) HLA disparities. Patients had either malignant (n=46) or non-malignant (n=17) disease. In all cases, graft-versus-host disease (GVHD) prophylaxis consisted of cyclospor-in A, short-term methotrexate and pretransplant anti-thymocyte globulin. The probability of haematopoietic recovery at day 100 was 97%. Two patients experienced primary graft failure. The cumulative probability of grades III-IV acute GVHD and of extensive chronic GVHD equalled 8 and 14%, respectively. A total of 12 patients died of transplant-related complications. The probability of transplant-related mortality (TRM) at 100 and 180 days was 10 and 15%, respectively, whereas the cumulative incidence of TRM was 22%. The probability of GVHD-related mortality equalled 6% at 2.5 years. The overall and disease-free survival rates were 67 and 65%, respectively. URD-HSCT with donor selection based on high-resoluti...Continue Reading

References

May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R SzydloM M Horowitz
Jun 1, 1997·Immunological Reviews·J A MadrigalJ M Goldman
Jun 17, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·V K PrasadS Y Yang
Feb 19, 2002·British Journal of Haematology·Franklin O SmithUNKNOWN National Marrow Donor Program
Apr 20, 2002·Blood·Nancy BuninUNKNOWN National Marrow Donor Program Working Group

❮ Previous
Next ❯

Citations

Jul 24, 2008·Bone Marrow Transplantation·F LocatelliF Moretta
Oct 16, 2007·Bone Marrow Transplantation·D A Jacobsohn
Dec 18, 2007·Bone Marrow Transplantation·V Rocha, F Locatelli
Nov 15, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Evgenios GoussetisPanagiotis Tsirigotis
Mar 24, 2010·Pediatric Clinics of North America·Kristin BairdKirk R Schultz
May 20, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Edoardo LaninoUNKNOWN Franca Fagioli for the AIEOP-HSCT Group
Nov 16, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Evgenios GoussetisStelios Graphakos
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carrie L KitkoJohn E Levine
May 2, 2014·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sergio RutellaFranco Locatelli
Jun 3, 2009·The Journal of Experimental Medicine·Nilu GoonetillekeAndrew J McMichael
Jun 25, 2014·The Journal of Experimental Medicine·Suzanne L CampionFederica Sallusto
Apr 20, 2011·The Journal of Infectious Diseases·Ruth SimmonsPaul Klenerman
Sep 3, 2011·PloS One·Tatenda MahlokozeraUNKNOWN Center for HIV/AIDS Vaccine Immunology
Jan 14, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Erin GatzaSung Won Choi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.